Dopaminagonists and fibrotic valvular heart disease: Further considerations
Identifieur interne : 003415 ( Istex/Curation ); précédent : 003414; suivant : 003416Dopaminagonists and fibrotic valvular heart disease: Further considerations
Auteurs : Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-12.
Abstract
Companion letters have been published in this issue of Movement Disorders: Chaudhuri et al., pp 1522–1523, and Horowski et al., pp 1523–1524.
Url:
DOI: 10.1002/mds.20328
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003415
Links to Exploration step
ISTEX:22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopaminagonists and fibrotic valvular heart disease: Further considerations</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>E-mail: rascol@cict.fr</mods:affiliation><country wicri:rule="url">France</country></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20328</idno><idno type="url">https://api.istex.fr/document/22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003415</idno><idno type="wicri:Area/Istex/Curation">003415</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopaminagonists and fibrotic valvular heart disease: Further considerations</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>E-mail: rascol@cict.fr</mods:affiliation><country wicri:rule="url">France</country></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-12">2004-12</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1524">1524</biblScope><biblScope unit="page" to="1525">1525</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250</idno><idno type="DOI">10.1002/mds.20328</idno><idno type="ArticleID">MDS20328</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">Companion letters have been published in this issue of Movement Disorders: Chaudhuri et al., pp 1522–1523, and Horowski et al., pp 1523–1524.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003415 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 003415 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250
|texte= Dopaminagonists and fibrotic valvular heart disease: Further considerations
}}
| This area was generated with Dilib version V0.6.23. |  |